Oncurie

Oncurie is a preclinical-stage biotechnology company specializing in the development of next-generation radiopharmaceuticals and radioisotope chelators for cancer diagnosis and treatment. Spun out of North Carolina State University, the company leverages a proprietary, customizable porphyrin platform to design targeted theranostic pairs. Its lead program, O5, is a folate receptor alpha (FRα)-targeting compound being developed as a theranostic pair using copper-64 for PET imaging diagnostics and copper-67 for targeted radionuclide therapy, primarily targeting ovarian cancer. Oncurie's technology aims to improve safety and efficacy by preventing in vivo dissociation of radioisotopes, offering a promising approach for aggressive and metastatic cancers.